Buy Stocks Easy | About Us
September 18, 2021
Buy Stocks Easy | Online Stocks

APVO


Buy Aptevo Therapeutics Inc. Stock (symbol: APVO) Easy Online

Company Name: Aptevo Therapeutics Inc.

Symbol: APVO

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2016

APVO Current Share Price

Today's APVO ( Aptevo Therapeutics Inc. ) opening price: $0.5792

Yesterday's APVO ( Aptevo Therapeutics Inc. ) closing price: $0.5663

Aptevo Therapeutics Inc. Stock ( symbol: APVO ) Price Chart since IPO (2016):

12 Months Aptevo Therapeutics Inc. Stock ( symbol: APVO ) Price Chart

Popular Questions about Aptevo Therapeutics Inc. Public Stock ( APVO )

A: Aptevo Therapeutics Inc. stock symbol (also called stock or share ticker) is APVO

A: Aptevo Therapeutics Inc. IPO (Initial Public Offering) took place on 2016

A: Aptevo Therapeutics Inc.'s stock (APVO symbol) price at ther IPO (initial Public Offering) was $0.5792

Q: Is APVO stock worth buying at the moment?

A: The APVO stock performance since 2019 are rather disappointing. If you had bought 1 share of Aptevo Therapeutics Inc. stock (symbol: APVO) at the beginning of 2019, at the opening share price of $1.6000, you would be left with exactly $0.5792 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Aptevo Therapeutics Inc. Stock Easy Online

Aptevo Therapeutics Inc. Stock Ticker Price Chart since IPO:





Aptevo Therapeutics Inc. Stock Price Yesterday



 


Aptevo Therapeutics Inc. Stock Price – Last Week




 


Aptevo Therapeutics Inc. Stock Price – Last Month




 


Aptevo Therapeutics Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/06/1957321/0/en/Aptevo-Therapeutics-Receives-Orphan-Drug-Designation-for-APVO436-for-the-Treatment-of-Acute-Myelogenous-Leukemia.html
                            

                                
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

                                
                                
SEATTLE, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Aptevo Therapeutics In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/03/1925032/0/en/Aptevo-Therapeutics-Provides-Corporate-and-Pipeline-Update.html
                            

                                
Aptevo Therapeutics Provides Corporate and Pipeline Update

                                
                                
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conve...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/19/1918004/0/en/Aptevo-Therapeutics-Introduces-New-Adaptir-Bispecific-Antibody-Candidate-Intended-for-the-Treatment-of-Solid-Tumors.html
                            

                                
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

                                
                                
New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific  Antib...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4287428-aptevo-therapeutics-ixinity-revenue-still-focus
                            

                                
Aptevo Therapeutics: IXINITY Revenue Still The Focus

                                
                                
IXINITY revenue increased for the quarter, which is what I wanted t...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/06/1957321/0/en/Aptevo-Therapeutics-Receives-Orphan-Drug-Designation-for-APVO436-for-the-Treatment-of-Acute-Myelogenous-Leukemia.html
                            

                                
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

                                
                                
SEATTLE, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Aptevo Therapeutics In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/03/1925032/0/en/Aptevo-Therapeutics-Provides-Corporate-and-Pipeline-Update.html
                            

                                
Aptevo Therapeutics Provides Corporate and Pipeline Update

                                
                                
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conve...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/19/1918004/0/en/Aptevo-Therapeutics-Introduces-New-Adaptir-Bispecific-Antibody-Candidate-Intended-for-the-Treatment-of-Solid-Tumors.html
                            

                                
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

                                
                                
New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific  Antib...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4287428-aptevo-therapeutics-ixinity-revenue-still-focus
                            

                                
Aptevo Therapeutics: IXINITY Revenue Still The Focus

                                
                                
IXINITY revenue increased for the quarter, which is what I wanted t...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/06/1957321/0/en/Aptevo-Therapeutics-Receives-Orphan-Drug-Designation-for-APVO436-for-the-Treatment-of-Acute-Myelogenous-Leukemia.html
                            

                                
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

                                
                                
SEATTLE, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Aptevo Therapeutics In...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/03/1925032/0/en/Aptevo-Therapeutics-Provides-Corporate-and-Pipeline-Update.html
                            

                                
Aptevo Therapeutics Provides Corporate and Pipeline Update

                                
                                
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conve...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/19/1918004/0/en/Aptevo-Therapeutics-Introduces-New-Adaptir-Bispecific-Antibody-Candidate-Intended-for-the-Treatment-of-Solid-Tumors.html
                            

                                
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

                                
                                
New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific  Antib...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4287428-aptevo-therapeutics-ixinity-revenue-still-focus
                            

                                
Aptevo Therapeutics: IXINITY Revenue Still The Focus

                                
                                
IXINITY revenue increased for the quarter, which is what I wanted t...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.